Compositions, systems, and methods for detection of ovarian cancer
OwnerManson Fok, Kang Zhanginventors
Life of this patent
Estimating the term…
Abstract
Compositions and methods for diagnosis and evaluation of prognosis of epithelial ovarian cancer (EOC) are provided. Development of an artificial intelligence approach entitled MethylBert and its application to identification of methylation sites useful in identification of EOC from cell free DNA obtained from serum or plasma is shown. PCR-based methods directed to the methylation state of the OV-1 site identified using MethylBERT approach can be used in screening for EOC using cell free DNA obtained from blood samples, and can be combined with measurement of tumor markers associated with EOC.
Claims21
A method of assisting in diagnoses of endothelial ovarian cancer, comprising:
- isolating cell-free genetic material from an individual;
- and
- characterizing nucleic acid methylation of one or more genetic markers selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22,
- wherein aberrant methylation of one or more genetic marker is indicative of endothelial ovarian cancer.
A method of assisting in determining a prognosis for endothelial ovarian cancer, comprising:
- isolating cell-free genetic material from an individual;
- and
- characterizing nucleic acid methylation of one or more genetic markers selected from the group consisting of OV1, OV2, OV6, OV3, [[ ]]OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22,
- wherein aberrant methylation of one or more genetic marker is indicative of a poor prognosis for endothelial ovarian cancer.
A composition for diagnosis or prognosis of endothelial ovarian cancer, comprising:
- a first primer that is complementary to a first portion of nucleic acid proximal to at least one genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22;
- and
- a probe that is complementary to at least one genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22 and that comprises a first dye or a first fluorophore.
(canceled)
Dependencies are inferred from the claim text.